Intuitive Surgical (NASDAQ:ISRG – Get Free Report) had its target price hoisted by equities researchers at Leerink Partners ...

In a report released on January 16, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from Outperform to Market Perform. Analyst Price Forecast Suggests 6.67% Upside As of ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00.

Leerink Partners’ price target would indicate a potential upside of 95.50% from the stock’s current price. VIR has been the subject of several other reports. Needham & Company LLC reiterated a ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Fintel reports that on December 12, 2024, Leerink Partners downgraded their outlook for LAVA Therapeutics N.V. (NasdaqGS:LVTX) from Outperform to Market Perform. Analyst Price Forecast Suggests ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (WBAG:ALGN) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (LSE:0HCK) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

Align Technology upgraded to Outperform with a $280 price target by Leerink Partners. Q3 adjusted EPS beats at $2.35, while sales rose 1.8% to $977.9 million. Align Technology — a medical device ...